Document is current
Any future updates will be listed below
-
Authors
McLeman, Bethany http://orcid.org/0000-0001-5382-7114
Gauthier, Phoebe
Lester, Laurie S.
Homsted, Felicity
Gardner, Vernon III
Moore, Sarah K.
Joudrey, Paul J.
Saldana, Lisa
Cochran, Gerald
Harris, Jacklyn P.
Hefner, Kathryn
Chongsi, Edward
Kramer, Kimberly
Vena, Ashley
Ottesen, Rebecca A.
Gallant, Tess
Boggis, Jesse S.
Rao, Deepika
Page, Marjorie
Cox, Nicholas
Iandiorio, Michelle
Ambaah, Ekow
Ghitza, Udi
Fiellin, David A.
Marsch, Lisa A.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05310786 at ClinicalTrials.govDocuments that mention this clinical trial
Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations
https://doi.org/10.1186/s13722-024-00452-y
-
Funding
Funding for this research was provided by:
National Drug Abuse Treatment Clinical Trials Network (UG1DA030409)
- License Information
-
More Information
Article History
Received: 3 November 2023
Accepted: 11 March 2024
First Online: 18 March 2024
Declarations
:
: This study was approved by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board. Consent procedures include a partial waiver of HIPAA consent to identify potential patient candidates, a verbal consent to conduct screening and retain those data, a written informed consent to participate in the study, and a verbal consent to participate in qualitative interviews for a subset of participants. In addition, a waiver of consent was granted for the collection of electronic health record data, which will include a limited dataset.
: Not applicable.
: The authors declare that they have no competing interests to this work.
